Is The Bull Market A Bargain Or Broken?

Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?

CIO Weekly: 3 Tests To The Equities Rally

Stocktwits Pharma Pulse: Big Pharma Earnings, Cancer Updates And 2 FDA Deadlines — The Week’s Biotech Watchlist

Iovance’s Melanoma Therapy Shows Promising 4-Year Data – Retail Says Acquisition Imminent Before 2027-End

Ionis Pharmaceuticals Secures FDA Orphan Drug Designation For Rare Epilepsy Treatment

Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?

Revisiting Former Stock Picks Marriott, Logitech, Harmony Biosciences

Why $55 Million Flowed Into a Triple-Leveraged Biotech ETF Worth Less Than $600 Million

Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In

AI Bubble: It's Not One Bubble, But Three Ready To Burst

UNH Stock Outpaces S&P 500 In 2026, Eyes Best Year Since Pandemic — CFO Says Wall Street May Be Missing 2027 Upside

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist

Better Healthcare ETF: Fidelity's Broad, Low-Cost FHLC vs. State Street's XBI Targeting Biotech

Better State Street Healthcare ETF: XBI's Biotech Focus vs. XPH Targeting Pharmaceuticals